EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD
Enveric Biosciences (NASDAQ:ENVB) has secured its first U.S. patent for the EVM401 Series, a novel collection of non-hallucinogenic, mescaline-derived compounds. These compounds are designed to address addiction, ADHD anxiety, and other neuropsychiatric disorders, potentially offering new therapeutic avenues for patients who have limited options.
What Happened
Issued on January 14, 2025, the patent titled “Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives” covers compounds that uniquely modulate critical brain receptors associated with mental health conditions. Specifically, these molecules target the alpha-2A adrenergic receptor (ADRA2A), the serotonin 5-HT2C receptor and the dopamine transporter (DAT) – all of which play pivotal roles in neurological functions and therapeutic potential.
Speaking exclusively to Benzinga, Dr. Joseph Tucker, CEO of Enveric Biosciences, said, “With the issuance of this patent, we are …